Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Cardiac sarcoma

A cardiac sarcoma is a primary malignant mesenchymal neoplasm of the heart, characterized by growth that may involve the endocardium, myocardium, epicardium and adjacent structures. The term encompasses several histological subtypes that share the same anatomical site but differ in cellular differentiation, molecular alterations and treatment sensitivity. Diagnosis also requires establishing that the heart is the site of origin: an extracardiac sarcoma that has metastasized to the heart or extended through a vessel represents a different oncological problem.

Sarcomas are the predominant group among primary malignant cardiac tumors in adults, within an overall very rare disease category. They often occur in relatively young adults, although the age range is broad. The distribution of histological subtypes differs substantially between surgical cohorts, pathology series and registries; molecular reassessment of tumors formerly classified as undifferentiated has further changed these proportions. Therefore, the frequencies observed at a specialist center reflect its patient population and diagnostic criteria as well as disease biology.

The clinical significance arises from the interaction between biological aggressiveness and anatomical constraints. In the heart, obtaining a wide margin of healthy tissue is often impossible without sacrificing structures essential to circulation. Moreover, obstruction of a valvular orifice may require intervention before preoperative therapy is completed, whereas a less obstructive infiltrating tumor may already have disseminated when detected. Management must therefore integrate local control, metastatic risk and functional urgency.

Etiology, classification and molecular basis

Most cases are sporadic and have no demonstrable causal factor. Associations established for soft-tissue sarcomas, such as certain hereditary syndromes and tumors arising in previously irradiated fields, require individual assessment at the cardiac site. Very early onset, multiple tumors and familial clustering warrant genetic evaluation; an isolated cardiac sarcoma does not automatically imply a syndrome. Somatic alterations in the tumor must be distinguished from heritable germline variants.

Cardiac angiosarcoma shows endothelial differentiation and a marked predilection for the right atrium. Intimal sarcomas and several pleomorphic tumors frequently involve the left atrium. Leiomyosarcoma exhibits a smooth-muscle phenotype and may affect the region of the pulmonary vein ostia. Rhabdomyosarcoma shows skeletal-muscle differentiation and may also occur in children. Typical locations help select diagnostic hypotheses for testing but do not themselves constitute histological criteria.

Undifferentiated pleomorphic cardiac sarcoma is a diagnosis of exclusion after an adequate search for specific lines of differentiation. In some tumors with undifferentiated morphology, genetic testing identifies MDM2 amplification, an important finding in the classification of intimal sarcoma. Immunohistochemical MDM2 expression may provide guidance but requires interpretation and molecular confirmation when appropriate. Historical terminology, including “malignant fibrous histiocytoma,” cannot be applied uncritically to contemporary classification.

Other entities require particularly close correlation between morphology and genetics. Synovial sarcoma is associated with SS18 rearrangement and the corresponding fusion with an SSX gene, although the cardiac location does not contain synovium and the name cannot be interpreted literally. Cardiac osteosarcoma requires demonstration of osteoid produced by malignant cells and exclusion of a relevant skeletal primary tumor. Radiological calcification, myxoid tissue and a merely spindle-shaped cellular appearance are descriptive findings, none of which is sufficient on its own to define a histological subtype.

The molecular pathogenesis involves abnormalities of cell-cycle control, genomic stability and growth pathways, in combinations that differ among subtypes. Complex genomes predominate in some tumors; in others, a characteristic fusion has diagnostic value. Identifying a potentially targetable alteration may prompt therapeutic discussion, but biological activity of a pathway and availability of a drug targeting it do not constitute demonstrated clinical efficacy in cardiac sarcoma. This distinction is essential when interpreting extensive molecular profiling reports.

Tumor growth and pathophysiology

A sarcoma may develop an intracavitary component, an intramural component or both. Expansion into the lumen causes mechanical obstruction; invasion of the wall replaces myocardium, alters compliance and may reach the coronary arteries or conduction system. Necrosis occurs when growth exceeds the available blood supply, while hemorrhage and intratumoral thrombosis contribute to heterogeneity. The apparent margin on imaging may therefore contain viable infiltrating tissue beyond the most conspicuous part of the mass.

In the left heart, an atrial lesion may obstruct mitral flow or pulmonary venous inflow, increasing pulmonary venous pressure and causing dyspnea and sometimes pulmonary edema. A mobile component can prolapse through the valve, making obstruction dynamic. Ventricular involvement reduces ejection capacity or affects the subvalvular apparatus and outflow tract. Surface fragmentation and adherent thrombus can produce arterial emboli even before the mass causes overt heart failure.

In the right heart, obstruction of caval venous return or tricuspid inflow causes systemic congestion and reduced ventricular filling. Pericardial extension may add tamponade; invasion of the right coronary artery may impair myocardial perfusion and conduction. Tumor and thrombotic emboli may reach the pulmonary arterial tree. Hematogenous dissemination may affect the lungs and other organs, with a distribution influenced by subtype and natural history.

Infiltrative disease promotes arrhythmias through conduction discontinuities, ischemia and involvement of specialized tissue. Systemic inflammation, anemia and catabolism further reduce the patient's reserve. Symptoms and severity therefore depend on location, growth rate and affected structures, as well as diameter. A reduction in size during treatment must be interpreted alongside restoration of flow, wall stability and chamber function.

Clinical presentation and bedside assessment

Suspicion may arise from new-onset heart failure, persistent pericardial effusion, syncope, palpitations or an embolic event. Dyspnea is often initially attributed to more common conditions; rapid worsening or a mismatch between symptoms and known heart disease should prompt reassessment. Chest pain, low-grade fever, fatigue and weight loss may precede identification of the mass. Metastases may also cause the first clinical manifestation.

The medical history should clarify symptom duration and progression, relationships to posture and exertion, episodes of hemoptysis, neurological deficits and bone pain. Previous tumors, thoracic irradiation, family history, anticancer treatments and conditions predisposing to thrombosis or endocarditis should be investigated. A previous diagnosis of myxoma followed by early recurrence, infiltrative growth or poorly defined histological reports warrants review of the original material. Comparing previous images helps distinguish postoperative residual tissue from a new lesion.

Physical examination assesses perfusion and congestion through blood pressure, heart rate, oxygen saturation, peripheral temperature, mental status and urine output, together with cardiopulmonary findings. Jugular venous distension, edema, hepatomegaly and ascites suggest right-sided involvement; crackles and orthopnea point toward pulmonary venous hypertension. A murmur may reflect a tumor-related gradient or regurgitation. Neurological examination and a search for peripheral ischemic signs complete the assessment of possible embolic consequences.

Hemodynamic stability determines the sequence of investigations. In stable patients, there is time for full characterization and a planned biopsy. With tamponade, severe obstruction or rapid deterioration, a procedure needed to restore circulation may precede complete staging. Even in emergencies, whenever possible, tissue sampling and margin documentation should be agreed upon, because an intervention performed to preserve function influences subsequent oncological control.

Imaging and diagnostic investigations

Echocardiography shows the mass's relationships to the wall, valves and blood flow. Doppler assessment quantifies obstruction and regurgitation; examination of the pericardium and venae cavae clarifies any filling impairment. Transesophageal echocardiography may be necessary for the left atrium, pulmonary veins and poorly accessible structures. Broad-based attachment, invasion and extension beyond a chamber increase the likelihood of sarcoma, but echocardiographic appearances still overlap with thrombi and other tumors.

Multiparametric magnetic resonance imaging defines the tumor–myocardium interface, intramural distribution and viable tissue in relation to necrosis, blood and thrombus. Perfusion and contrast enhancement aid characterization; cine sequences reveal dynamic interference with valves and chambers. The protocol must be adapted to the clinical question and patient tolerance, considering rhythm, implanted devices and renal function. A heterogeneous mass requires assessment of its different components: a poorly perfused area may be necrosis or thrombus within a neoplasm.

Cardiac CT delineates coronary and vascular relationships, calcifications, extracardiac extension and potential reconstruction planes. Staging chest CT simultaneously assesses the lungs. For tumors near coronary arteries, the examination should answer the surgical question of contact, compression or encasement while acknowledging resolution limits in distinguishing microscopic invasion. Invasive coronary angiography is reserved for questions where it adds information useful for planning.

FDG PET/CT may clarify indeterminate extracardiac sites, guide sampling toward a viable region and document metabolic activity in selected settings. Uptake is influenced by preparation, myocardial metabolism, inflammation and recent treatments; by itself, it establishes neither histological subtype nor resectability. Its use should address a specific question, with CT and MRI remaining central to anatomical assessment. Serial comparisons require sufficiently consistent protocols.

Blood tests assess anemia, inflammation, organ function and coagulation; troponin and natriuretic peptides may complement assessment of cardiovascular injury. There is no specific serum marker capable of confirming or excluding cardiac sarcoma. The differential diagnosis includes myxoma, thrombus, vegetation, lymphoma and metastatic tumors. A left atrial mass extending into the venous ostia or posterior wall deserves particular attention even when its intracavitary portion resembles a myxoma.

Biopsy, pathology and grading

An adequate tissue diagnosis is generally required before oncological treatment. The target is selected after reviewing imaging: an accessible extracardiac site may be preferable, whereas intracardiac sampling must minimize perforation, bleeding and embolization. Risk is greater for vascular tumors and mobile masses in the left heart. If prompt resection is already indicated and feasible, examination of the surgical specimen can establish the diagnosis; preliminary biopsy is not an automatic step regardless of circumstances.

Sampling must include enough viable tissue to assess heterogeneity. A necrotic or thrombotic fragment may be inconclusive; a small biopsy may also underestimate grade. Morphological assessment examines architecture, line of differentiation, atypia, mitoses, necrosis and any matrix produced by the tumor. Immunohistochemistry is selected according to the differential diagnosis, including vascular, muscular, epithelial or lymphoid markers as appropriate, rather than assigning absolute significance to a single positive result.

Molecular diagnostics using FISH, fusion analysis or sequencing complement uncertain cases and those with specific features or possible therapeutic implications. Evidence of MDM2 amplification or an SS18-SSX fusion must be correlated with the full picture and site of origin. A negative technical result from scant material requires cautious interpretation. Expert-center review is particularly valuable when the report remains limited to generic terms such as “malignant spindle-cell neoplasm.”

Histological grade is reported using the system appropriate for the subtype; the FNCLCC system, when applicable, integrates differentiation, mitotic activity and necrosis. Its usefulness in sarcomas does not eliminate limitations in validation at the rare cardiac site or in entities with distinct biological characteristics. The surgical specimen report should document size, infiltrated structures, margins and, after preoperative treatment, the amount and distribution of viable tumor and treatment-induced changes. The report must inform clinical decisions as well as name the lesion.

Staging and assessment of resectability

Systemic staging includes a CT search for pulmonary metastases and extends to other regions according to subtype, symptoms and findings. The abdomen and pelvis matter for subtypes with relevant dissemination patterns; brain imaging is indicated with neurological symptoms and is also considered without symptoms in at-risk subtypes, particularly angiosarcoma. Suspicious bone or nodal lesions require targeted investigation. Confirmation of a finding that would fundamentally change treatment intent may warrant an additional biopsy.

Assessing local resectability involves determining whether all tumor can be removed while reconstructing effective circulation. Infiltration of an atrial wall may allow reconstruction; extensive involvement of ventricular myocardium, coronary arteries, several valves or great vessels may make the plan much more complex. The assessment requires oncological cardiac surgery expertise and may change after treatment response. Size and absence of metastases, considered alone, are insufficient to establish operability and expected benefit.

R0 denotes resection with no tumor at microscopic margins, R1 denotes microscopic residual tumor and R2 denotes macroscopic residual tumor. These categories are not synonymous with hemodynamically successful surgery: an R2 procedure may relieve obstruction while pursuing a different oncological goal. General staging systems and nomograms developed for sarcomas at other sites must be used with recognition of their limited transferability to the heart.

Surgery and local treatment

In patients with localized disease and adequate clinical condition, radical resection offers the main possibility of durable local control. Surgery may require atrial wall excision, patch reconstruction, valvular procedures, vascular reconstruction or revascularization. Planning must also anticipate the risk of conduction defects and ventricular dysfunction. The goal is to combine oncologically adequate margins with residual function, avoiding the assumption that simply excising the intracavitary portion constitutes radical treatment.

For certain complex left-sided tumors, highly specialized centers have used cardiac autotransplantation, involving temporary explantation, extracorporeal resection and reconstruction, followed by reimplantation of the patient's own heart. This is an access and reconstruction technique requiring strict selection and does not involve the immunosuppression needed for donor transplantation. Donor heart transplantation remains exceptional for sarcomas because of occult disease and recurrence risks under immunosuppression; it is not the standard solution when resection is impossible.

Palliative surgery or debulking may be discussed when mechanical obstruction dominates the immediate prognosis and a limited intervention offers realistic benefit. Assessment includes the anticipated duration of relief, perioperative risk, dissemination and prospects for starting or continuing systemic therapy. Similarly, resection of recurrence is considered according to disease-free interval, disease distribution and feasibility. Associations between surgery and survival reported in clinical series are affected by selection of operable patients and do not themselves measure causality.

Radiotherapy may contribute to control of residual disease, recurrences or unresectable lesions in selected situations. The target moves with heartbeat and respiration and lies adjacent to sensitive structures; integrated imaging, motion management and individualized dose constraints are required. Evidence from extremity and trunk sarcomas does not justify automatically transferring indications and doses to the heart. Local benefit, acute and late toxicity and life expectancy must be discussed together.

Systemic therapy and multimodal strategy

Neoadjuvant chemotherapy may be offered to stable patients with potentially resectable disease, especially when shrinkage could improve margins. It also provides information on biological sensitivity and treats possible microscopic dissemination early. Risks include local progression during the waiting period or toxicity that reduces operability. It therefore requires a confirmed diagnosis, a defined goal and close reassessment; critical obstruction may make surgery the priority.

Anthracyclines are an important foundation of therapy for advanced sarcomas, with selection tailored to subtype and cardiac function. Adding ifosfamide may be considered when achieving tumor shrinkage has particular clinical value and the patient can tolerate greater toxicity. In soft-tissue sarcomas, the increased likelihood of tumor reduction with the combination does not automatically translate into a survival advantage for everyone. The cardiac location calls for additional assessment of reserve before using potentially cardiotoxic agents.

The histological subtype guides alternatives and later lines: taxanes for angiosarcoma, gemcitabine combinations in suitable subtypes, trabectedin mainly in specific sarcomas and pazopanib in some previously treated non-adipocytic sarcomas exemplify options to discuss in the appropriate context. There are also data on doxorubicin combined with trabectedin for leiomyosarcoma. Choices at the cardiac site often rely on extracardiac evidence and must consider expected benefit, toxicity, previous treatments and regulatory availability.

The role of adjuvant treatment after resection is individualized. Margins, subtype, systemic risk, response to any prior therapies and tolerability guide discussion; there is no cardiac-sarcoma-specific randomized evidence mandating one universal regimen. In metastatic disease, the goal may be control of progression and symptoms. Local treatment of oligometastatic disease is reserved for selected cases, assessing biological behavior and the possibility of controlling all relevant sites.

Molecular profiling may identify alterations actionable under tumor-agnostic indications or in clinical trials. Experimental targeted inhibitors and immunotherapy require justification based on subtype, biomarkers or a protocol; disease rarity alone does not make a treatment effective. Participation in trials and specialist networks is particularly valuable because it enables coherent selection and structured outcomes collection. In children, subtypes such as rhabdomyosarcoma require dedicated oncology protocols and expertise.

Response monitoring and cardiovascular protection

Before treatment, ventricular function, valves, blood pressure and rhythm are documented, along with biomarkers and myocardial strain when indicated. The tumor itself may already alter these parameters; subsequent changes must be attributed with consideration of progression, response, toxicity and intercurrent conditions. Cardio-oncology monitoring enables early treatment adjustments and discussion of cardioprotective strategies when appropriate, avoiding both unjustified interruptions and uncritical continuation despite significant injury.

The oncological response is assessed using comparable imaging, reproducible measurements and a search for new sites. General size criteria are useful, but a residual mass may contain necrosis or fibrosis; conversely, a modest change in volume may accompany substantial relief of obstruction. Echocardiography and MRI clarify flow, viable tissue, effusion and anatomical stability. Multidisciplinary reassessment determines whether to continue, change strategy or take advantage of a window of resectability.

Prognosis, recurrence and follow-up

Prognosis remains serious because of the risk of local recurrence and metastases, but individual courses vary widely. Localized disease, the ability to achieve complete resection, systemic response and good functional reserve may favor longer control. A negative margin reduces the problem of local residual disease without eliminating microscopic dissemination. Median survival figures from historical series, often small and mixing subtypes, should not be presented as individual predictions.

The surveillance plan encompasses the cardiac site and other regions at risk. During the early years, when the risk of high-grade sarcoma recurrence is greater, follow-up is generally more frequent; intervals and duration are tailored to the clinical profile. Chest CT detects pulmonary lesions, whereas echocardiography and MRI assess the surgical bed, reconstructions and function. Other investigations follow subtype and symptoms. Suspected recurrence must be distinguished from scar, thrombus or treatment changes before new therapy is assigned.

Quality of life is a substantive clinical outcome: the ability to eat and move, dyspnea, pain, sleep and procedural burden should be reassessed alongside radiological control. Early palliative care and anticancer therapy can proceed concurrently. When progression makes further benefit from intensive treatment unlikely, decisions are based on patient goals and the realistic prospect of alleviating symptoms.

Complications

Complications of the tumor include hemodynamic obstruction, pulmonary edema, systemic congestion, coronary ischemia, severe arrhythmias, atrioventricular block, tamponade and embolic events. Vascular or wall invasion may cause bleeding; metastatic spread adds organ failure, pain and neurological complications. Cancer-associated thrombosis and bleeding require individualized antithrombotic decisions, particularly with vascular or cerebral lesions.

Treatment may cause cardiac dysfunction, valvular or coronary injury, infections, hemorrhage, conduction abnormalities and problems with reconstructive materials. Chemotherapy and targeted treatments may cause bone marrow, renal, hepatic, neurological and cardiovascular toxicity; irradiation may add pericardial or myocardial injury. Integrated assessment helps distinguish these complications from tumor progression and select useful interventions without losing sight of disease control.

References
  1. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  2. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  3. Neuville A et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. The American Journal of Surgical Pathology. 2014;38(4):461-469.
  4. Serrano C et al. SEOM-GEIS Spanish clinical guidelines for the management of soft-tissue sarcomas (2024). Clinical and Translational Oncology. 2025;27(4):1460-1471.
  5. Ramlawi B et al. Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience. The Annals of Thoracic Surgery. 2016;101(2):698-702.
  6. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  7. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  8. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  9. Penel N et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. Journal of Clinical Oncology. 2008;26(32):5269-5274.
  10. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.